Clinical Trials Logo

Solid Malignancies clinical trials

View clinical trials related to Solid Malignancies.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05006794 Recruiting - Solid Malignancies Clinical Trials

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Start date: September 15, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase I open-label, multi-center study of GS-9716 tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose of GS-9716, and characterize the safety and tolerability of GS-9716 as monotherapy and in combination with anti-cancer therapies.

NCT ID: NCT04492735 Recruiting - Metastatic Disease Clinical Trials

The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies

Start date: June 5, 2020
Phase:
Study type: Observational

Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospective feasibility study of pediatric patients with solid malignancies with or without lung metastatases who present at the time of initial diagnosis or relapse. These patients will receive a targeted dye to aid in the resection of these metastases. We plan to assess ICG as it relates to: 1. Diagnostic accuracy using pathologic correlation as gold standard measure 2. Short and long term event free and overall survival